cimb-logo

Journal Browser

Journal Browser

Molecular Research in Chronic Dermatoses, 2nd Edition

A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 552

Special Issue Editors


E-Mail Website
Guest Editor
Department of Dermatology, Hospital Manises, 46940 Valencia, Spain
Interests: melanoma; clinical dermatology; cancer biomarkers; basal cell carcinoma; psoriasis; dermatopathology; dermatosurgery; skin biology; cosmetology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, Poland
Interests: hidradenitis suppurativa; hair disorders; psoriasis; inflammatory skin disorders; dermatological surgery; comorbidities; itch; psychodermatology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Chronic inflammatory dermatoses are a group of skin disorders characterized by recurrent and debilitating course and destructive influence on patients’ quality of life. The pathogenesis of most of them is not fully understood. Therefore, the treatment is challenging both for physicians and their patients, and the outcome is often unsatisfactory.

In recent years outstanding progress in understanding the molecular mechanisms behind the pathogenesis of inflammatory dermatoses has been made. The studies led to the development of new therapies, including biologics (chimeric, humanized, and human monoclonal antibodies) and their biosimilars, as well as systemic and topical small molecules (e.g. JAK inhibitors), which have revolutionized the management of patients suffering from chronic inflammatory dermatoses.

Nevertheless, there are still many unmet needs of currently available therapies. The insufficient availability and the high price of biologics impede their use in lower-income communities, while the adverse effects of JAK inhibitors may cause physicians hesitant about their prolonged use. Therefore, there is still a significant need for future, molecular research explaining the pathogenetic mechanisms leading to the development of skin lesions. In the future, these findings may build a foundation for new, targeted therapies, as well as for predicting disease course and its severity.

The special issue entitled “Molecular Research in Chronic Dermatoses, 2nd Edition” is now open for submission. Following with the first edition, our aim is to publish state of art articles about the molecular mechanisms in, among others, hidradenitis suppurativa, psoriasis, atopic dermatitis, alopecia areata, vitiligo, and chronic spontaneous urticaria. This Special Issue will accept review articles, original research, and updated information on the pathophysiology and molecular pathways.

Dr. Antonio Martorell-Calatayud
Dr. Piotr K. Krajewski
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dermatopathology
  • dermatosurgery
  • skin biology
  • molecular biology
  • genetics
  • JAK inhibitors
  • antibodies

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 719 KiB  
Review
Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
by Isabella J. Tan, Alicia Podwojniak, Aarushi Parikh and Bernard A. Cohen
Curr. Issues Mol. Biol. 2024, 46(4), 2975-2990; https://doi.org/10.3390/cimb46040186 - 30 Mar 2024
Viewed by 426
Abstract
The evolution of personalized medicine in dermatology signifies a transformative shift towards individualized treatments, driven by the integration of biomarkers. These molecular indicators serve beyond diagnostics, offering insights into disease staging, prognosis, and therapeutic monitoring. Specific criteria guide biomarker selection, ensuring attributes like [...] Read more.
The evolution of personalized medicine in dermatology signifies a transformative shift towards individualized treatments, driven by the integration of biomarkers. These molecular indicators serve beyond diagnostics, offering insights into disease staging, prognosis, and therapeutic monitoring. Specific criteria guide biomarker selection, ensuring attributes like specificity, sensitivity, cost feasibility, stability, rapid detection, and reproducibility. This literature review, based on data from PubMed, SCOPUS, and Web of Science, explores biomarkers in Hidradenitis Suppurativa (HS), Psoriasis, Atopic Dermatitis (AD), Alopecia Areata (AA), Vitiligo, and Chronic Spontaneous Urticaria (CSU). In HS, TNF-α, IL-1β, and MMPs serve as biomarkers, influencing targeted therapies like adalimumab and anakinra. Psoriasis involves biomarkers such as TNF-α, IL-23, and HLA genes, shaping treatments like IL23 and IL17 inhibitors. AD biomarkers include ECP, IL-4, IL-13, guiding therapies like dupilumab and tralokinumab. For AA, lipocalin-2, cytokines, and genetic polymorphisms inform JAK inhibitors’ use. Vitiligo biomarkers range from cytokines to genetic markers like TYR, TYRP1, guiding treatments like JAK inhibitors. CSU biomarkers encompass IgE, cytokines, and autologous serum tests, influencing therapies like omalizumab and cyclosporine. Comparing conditions, common proinflammatory markers reveal limited specificity. While some biomarkers aid diagnosis and standard treatments, others hold more scientific than clinical value. Precision medicine, driven by biomarkers, has shown success in skin malignancies. Future directions involve AI-powered algorithms, nanotechnology, and multi-omics integration for personalized dermatological care. Full article
(This article belongs to the Special Issue Molecular Research in Chronic Dermatoses, 2nd Edition)
Show Figures

Figure 1

Back to TopTop